艾司西酞普兰与喹硫平联合治疗首发抑郁症的效果分析  

Analysis of the Effect of Escitalopram and Quetiapine in the Treatment of First-episode Depression

作　　者：杨晓江[1] YANG Xiaojiang(Department of Psychiatry,Quanzhou Third Hospital,Quanzhou,Fujian Province,362121 China)

机构地区：[1]泉州市第三医院精神科,福建泉州362121

出　　处：《中外医疗》2021年第33期89-91,107,共4页China & Foreign Medical Treatment

摘　　要：目的探讨艾司西酞普兰与喹硫平联合治疗首发抑郁症的效果。方法方便选取2018年1月—2020年12月在该院就诊的116例首发抑郁症患者为研究对象,以随机数表法将其划分为两组。对照组58例患者应用艾司西酞普兰治疗,研究组58例在此基础上联合喹硫平治疗。比较两组患者的临床疗效、治疗前后的神经因子水平[髓鞘间隙蛋白(MBP)与神经营养因子(BDNF)],治疗前、治疗4周与8周时的认知功能[以重复性成套神经心理状态测验(RBANS)评价]以及不良反应情况。结果研究组治疗的总有效率为94.83%较对照组79.31%高,差异有统计学意义(χ^(2)=6.202,P<0.05)。治疗后,研究组MBP(4.52±0.85)ng/mL较对照组(5.79±0.69)ng/mL低,BDNF(27.52±4.03)ng/mL较对照组(24.33±5.00)ng/mL高,差异有统计学意义(t=8.834、3.783,P<0.05)。治疗4周与8周时,研究组RBANS评分(73.52±10.00)分、(78.62±10.40)分较对照组高(68.03±8.46)分、(71.32±9.05)分,差异有统计学意义(t=3.192,4.033,P<0.05)。研究组不良反应发生率为10.34%,对照组不良反应发生率为8.62%,差异无统计学意义(χ^(2)=0.100,P>0.05)。结论首发抑郁症患者应用艾司西酞普兰与喹硫平联合治疗能够提高临床疗效,改善神经因子水平与认知功能,安全性佳,具有临床推广价值。Objective To explore the effect of escitalopram and quetiapine in the treatment of first-episode depression.Methods Conveniently selected the 116 first-episode depression patients who visited the hospital from January 2018 to December 2020 for research.They were divided into two groups using a random number table.58 patients in the control group were treated with escitalopram,and 58 patients in the study group were treated with quetiapine on this basis.Compared the clinical efficacy of the two groups of patients,the levels of neurological factors[myelin interstitial protein(MBP)and neurotrophic factor(BDNF)]before and after treatment,and the cognitive function[in a repetitive set of neuropsychological status test(RBANS)evaluation]before and after treatment,4 weeks and 8 weeks of treatment,and adverse reactions.Results The total effective rate of treatment in the study group was 94.83%higher than 79.31%in the control group,the difference was statistically significant(χ^(2)=6.202,P<0.05).After treatment,MBP(4.52±0.85)ng/mL in the study group was lower than that in the control group(5.79±0.69)ng/mL,and BDNF(27.52±4.03)ng/mL was higher than that in the control group(24.33±5.00)ng/mL,the difference was statistically significant(t=8.834,3.783,P<0.05).In the treatment of 4 weeks and 8 weeks,the RBANS score of the study group was(73.52±10.00)points and(78.62±10.40)points higher than that of the control group(68.03±8.46)points and(71.32±9.05)points,the difference was statistically significant(t=3.192,4.033,P<0.05).The incidence of adverse reactions in the study group was 10.34%,and the incidence of adverse reactions in the control group was 8.62%,the difference was not statistically significant(χ^(2)=0.100,P>0.05).Conclusion The combined treatment of escitalopram and quetiapine in patients with first-episode depression can improve the clinical efficacy,improve the level of neurological factors and cognitive function,with good safety and clinical promotion value.

关 键 词：艾司西酞普兰 喹硫平 首发抑郁症 

分 类 号：R5[医药卫生—内科学]